A Biohaven Pharmaceutical migraine drug has won FDA approval, clearing the way to the market for a new treatment option for the millions of people who suffer from the debilitating condition.
The Biohaven (NYSE: BHVN) drug rimegepant (Nurtec) was developed for acute migraine in adults, treating a migraine attack as it occurs. The drug, a tablet, is designed to dissolve quickly and provide fast pain relief. It’s the first drug from the New Haven, CT-based company to earn a regulatory nod.
Migraine affects an estimated 39 million men, women, and children in the US, according to the Migraine Research… Read more »
UNDERWRITERS AND PARTNERS
